InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (28 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
28
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Young Jonathan, Chief Operating Officer. Insider active across 1 company, notably Akero Therapeutics, Inc.. Cumulatively, 52 disclosures have been recorded. Split: 0 buy · 28 sells. Total volume traded: €5.1m. Activity tracked since 3 May 2021. The latest transaction was disclosed on 2 September 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Declarations52 total
152,616 sharesCommon StockSEC:0001193125-25-312092:0
20,000 sharesCommon StockSEC:0001193125-25-312092:1
20,000 sharesCommon StockSEC:0001193125-25-312092:2
20,000 sharesCommon StockSEC:0001193125-25-312092:3
47,573 sharesCommon StockSEC:0001193125-25-312092:4
12,500 shares@ US$21.10Common StockSEC:0001779805-25-000007:0
12,500 shares@ US$21.103.0% of flowCommon StockSEC:0000950170-25-108234:0
890 shares@ US$23.8680.2% of flowCommon StockSEC:0000950170-25-093321:0
1,453 shares@ US$54.841.0% of flowCommon StockSEC:0000950170-25-088635:0
2,493 shares@ US$53.9931.7% of flowCommon StockSEC:0000950170-25-085667:0
607 shares@ US$44.880.3% of flowCommon StockSEC:0000950170-25-039745:0
11,447 shares@ US$44.1686.2% of flowCommon StockSEC:0000950170-25-033998:0
5,100 shares@ US$53.5653.4% of flowCommon StockSEC:0000950170-25-014188:0
43,064 shares@ US$6.3643.4% of flowCommon StockSEC:0000950170-25-009326:0
10,000 shares@ US$28.0333.5% of flowCommon StockSEC:0000950170-25-001850:0
24,300 shares0Common StockSEC:0000950170-24-138152:0
2,503 shares@ US$30.790.9% of flowCommon StockSEC:0000950170-24-136023:0
10,000 shares@ US$32.1313.9% of flowCommon StockSEC:0000950170-24-133434:0
15,481 shares@ US$32.2675.9% of flowCommon StockSEC:0000950170-24-121102:2
292 shares@ US$32.9370.1% of flowCommon StockSEC:0000950170-24-121102:3
40,716 shares@ US$21.0910.1% of flowCommon StockSEC:0000950170-24-121102:0
34,943 shares@ US$31.25412.8% of flowCommon StockSEC:0000950170-24-121102:1
40,000 shares@ US$21.099.9% of flowCommon StockSEC:0000950170-24-115139:0
10,000 shares@ US$28.1773.3% of flowCommon StockSEC:0000950170-24-112672:0
568 shares@ US$26.180.2% of flowCommon StockSEC:0000950170-24-106473:0
25 of 52 declarations
About Young Jonathan
Jonathan Young is tied to Akero Therapeutics, Inc. SEC filings state that he is a co-founder and Chief Operating Officer, and that he had been in that role by 2020 after serving as President and Chief Executive Officer from April 2017 to September 2018. Recent SEC documents also list Form 4 filings by Jonathan Young in 2025, confirming he remained an Akero executive at that time. Sources: https://www.sec.gov/Archives/edgar/data/1744659/000110465920051294/tm2016707-1_def14a.htm
